Skip to main content

Table 4 Logistic regression analyses predicting the probability of prostate cancer

From: Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study

Predictors

AUC of individual predictor variable (95% CI);

P value*

Bivariate analysis

OR(95%CI);

P value

Multivariate analysis

Base model **

OR (95%CI); P value

Base model + %p2PSA

OR (95%CI); P value

Base model + PHI

OR (95%CI); P value

Age

0.66

(0.57–0.74) 0.470

1.077

(1.03–1.13); 0.002

1.063

(1.01–1.12); 0.014

1.070

(1.02–1.13); 0.011

1.068

(1.01–1.13); 0.013

tPSA, ng/mL

0.63

(0.54 − 0.71) -

1.100

(1.04–1.16); 0.001

1.064

(0.96–1.18); 0.252

1.049

(0.95 − 1.16); 0.335

1.013

(0.93–1.10); 0.761

fPSA

0.57

(0.48–0.65) 0.117

1.543

(1.06–2.25); 0.024

1.036

(0.51–2.10); 0.921

1.012

(0.52–1.97); 0.971

0.886

(0.48–1.65); 0.701

%fPSA

0.69

(0.61–0.77) 0.203

0.927

(0.88–0.98); 0.004

0.943

(0.87–1.03); 0.181

0.947

(0.87–1.03); 0.193

0.959

(0.89–1.04); 0.294

p2PSA, pg/mL

0.69

(0.60–0.76) 0.157

1.021

(1.01–1.04);

0.001

%p2PSA

0.72

(0.63–0.78) 0.109

1.708

(1.31–2.22); < 0.001

1.550

(1.18–2.04); 0.002

PHI

0.76

(0.67–0.82) 0.005

1.017

(1.01–1.02); < 0.001

1.015

(1.01–1.02); 0.002

AUC of multivariate models (95% CI);

0.736

(0.66–0.81)

< 0.001

0.793

(0.72–0.86)

< 0.001

0.796

(0.72–0.86)

< 0.001

Gain in predictive accuracy (95% CI);

P value

0.056

(− 0.0–0.11);

0.058

0.060

(0.00–0.12);

0.037

  1. AUC, area under the receiver operating characteristic curve; PSA, prostate-specific antigen; fPSA, free PSA; p2PSA, [-2]proPSA; PHI, prostate health index; tPSA, total PSA; OR, odds ratio; CI, confidence interval
  2. *P value: Comparison of AUC using tPSA as standard
  3. **Base model includes age, tPSA, fPSA and %fPSA
  4. P value to be statiscally significant with bolditalics